Neoadjuvant Chemotherapy for Different Stages of Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis

Table 1

Characteristics and interventions of studies included in the meta-analysis.

Author	Year	Country	Study design	Cancer stage	NAC regimen	NAC cycles	Interventions	Number of NAC+RC	Number of RC only	Number of the whole sample size	Median follow-up (months)
Kubota [24]	2021	Japan	Retrospective multicenter	cT2 and cT3-4	Cisplatin-based	3 or 4 cycles	NAC followed by RC versus RC alone	83	178	261	23
Soria [31]	2021	Europe, Canada and the USA	Retrospective multicenter	cT2	Cisplatin-based combination therapy.	3 cycles	NAC followed by RC versus RC alone	316	303	619	18
Mazzone [21]	2019	SEER database	Retrospective multicenter	cT2	NA	NA	NAC followed by RC versus RC alone	1519	2459	3978	NA
Lane [20]	2019	SEER database	Retrospective multicenter	cT2 and cT3-4	Cisplatin-based	NA	NAC followed by RC versus RC alone	381	1505	1886	25
Russell [22]	2019	Sweden	Retrospective multicenter	cT2 and cT3-4	NA	NA	NAC followed by RC versus RC alone	216	216	432	22
Nitta [23]	2019	Japan	Retrospective multicenter	cT2 and cT3-4	GC, MVAC, carboplatin, or GN	NA	NAC followed by RC versus RC alone	69	71	140	54
Hermans [19]	2018	Netherlands	Retrospective multicenter	cT2 and cT3-4	NA	NA	NAC followed by RC versus RC alone	191	4164	4355	118
Kitamura [17]	2014	Japan	Prospective multicenter	cT2 and cT3-4	MVAC	2 cycles	NAC followed by RC versus RC alone	64	66	130	55
Osman [18]	2014	Egypt	Prospective multicenter	cT2 and cT3-4	GC	3 cycles	NAC followed by RC versus RC alone	30	30	60	36
Khaled [32]	2014	Egypt	Prospective multicenter	cT3	GC	3 cycles	NAC followed by RC versus RC alone	59	55	114	37
Rosenblatt [33]	2012	Northern Europe	Retrospective multicenter	cT2 and cT3	Cisplatin+doxorubicin or cisplatin+MTX	2 or 3 cycles	NAC followed by RT+RC or RC versus RT+RC or RC	225	224	449	60
Sherif [11]	2004	Northern Europe	Prospective multicenter	cT2 and cT3	Cisplatin+doxorubicin or cisplatin+MTX	2 or 3 cycles	NAC followed by RT+RC or RC versus RT+RC or RC	306	314	620	56
Grossman [16]	2003	U.S.	Prospective multicenter	cT2 and cT3-4	MVAC	3 cycles	NAC followed by RC versus RC alone	153	154	307	101
Sherif [34]	2002	Northern Europe	Prospective multicenter	cT2 and cT3-4	Cisplatin+doxorubicin or MTX	3 cycles	NAC followed by RC versus RC alone	155	154	309	64
Malmström [35]	1996	Northern Europe	Prospective multicenter	cT2 and cT3-4	Cisplatin+doxorubicin	2 cycles	NAC followed by RT+RC versus RT+RC	151	160	311	60

GC: gemcitabine and cisplatin; GN: gemcitabine and nedaplatin; MTX: methotrexate; MVAC: methotrexate, vinblastine sulfate, doxorubicin hydrochloride (Adriamycin), and cisplatin; NA: not available; NAC: neoadjuvant chemotherapy; RC: radical cystectomy; RT: radiotherapy.